Following the announcement with Apertus Pharmaceutical, St. Louis Inno Business Journal highlighted the API Innovation Center’s collaborative efforts to manufacture lomustine, a crucial treatment for glioblastoma. The API Innovation Center’s investment in Apertus will establish an “oncology production suite” in the St. Louis region, equipped with advanced technology for generic lomustine manufacturing, showcasing the API Innovation Center’s dedication to strengthening the U.S. pharmaceutical supply chain. This partnership underscores the API Innovation Center’s commitment to addressing critical healthcare needs and advancing domestic drug production. The article also highlights strategic partnerships with the Glioblastoma Foundation and Missouri Technology Corporation, emphasizing our role in fostering and investing in innovation within the pharmaceutical sector. 

Read the St. Louis Inno Article